The company resumed production of the first batch of protamine produced in Beijing

In response to the current problem of shortage of protamine, a drug that must be used for heart surgery, the Beijing Drug Administration actively coordinated and required Beijing-qualified companies to resume production of the drug. Currently, the first batch of drugs has passed the inspection and has been listed. Products will be gradually supplied to the country.

In early August, after knowing that there was a shortage of protamine in individual hospitals, the Beijing Municipal Bureau of Food and Drug Administration took an active role in monitoring the supply and demand of the drug. It was learned that at present there is only one pharmaceutical factory in Shanghai, because of the supply of raw materials, the production stopped. Market supply tensions. As many of the top three hospitals in Beijing are using “protamine,” many heart patients with heart disease go to Beijing for medical treatment. The annual demand for the drug is about 100,000, and the country’s demand is the largest. At present, only one company in Beijing Hyatt Pharmaceutical Co., Ltd. of Yuekang Pharmaceutical Group owns the drug symbol, but has not produced it for a long time. In this regard, the Beijing Municipal Bureau of Food and Drugs took the initiative to assist companies in organizing industry experts to conduct "consultation" on production technology issues, enhance the company's production capacity, and strengthen the quality supervision of pharmaceuticals.

The reporter learned that at present, the first batch of products produced by Hyatt Pharmaceuticals Kaiyue Pharmaceutical has passed the inspection and listing. The Beijing Municipal Food and Drug Administration will further coordinate the company's efforts to organize production, increase market supply, and do its utmost to supply supplies to the country one after another to support the urgent needs of other provinces and municipalities for this medicine.